Bharat Biotech, Serum Institute To Start Trial Of Late-Stage Intranasal COVID-19 Vaccine Soon

New Delhi: Union Health Minister Harsh Vardhan said that late-stage clinical trials of intranasal COVID-19 vaccines are expected to be pursued by Serum Institute of India and Bharat Biotech once they receive regulatory approval.

The minister also said the late-stage trial usually involves 30,000 to 40,000 participants. Currently, the vaccines currently in Phase 3 trials are administered by injection, as per the World Health Organization (WHO).

According to India’s Dr Reddy’s Laboratories Ltd and the Russian Direct Investment Fund (RDIF) on Saturday, they have received renewed approval for performing late-stage clinical trials in India of the Russian COVID-19 vaccine.

In the past 24 hours, India’s coronavirus infections surged by another 61,871, data released on Sunday showed.

Get real time updates directly on you device, subscribe now.

Comments are closed.